• Citer

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

par Van Cutsem, Eric;Vervenne, Walter L;Bennouna, Jaafar;Humblet, Yves;Gill, Sharlene;Van Laethem, Jean-Luc ;Verslype, Chris;Scheithauer, Werner;Shang, Aijing;Cosaert, Jan;Moore, Malcolm J
Référence Journal of clinical oncology, 27, 13, page (2231-2237)
Publication Publié, 2009-05

Article révisé par les pairs

• Détails
• Contenu

Titre:	Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Auteur:	Van Cutsem, Eric; Vervenne, Walter L; Bennouna, Jaafar; Humblet, Yves; Gill, Sharlene; Van Laethem, Jean-Luc; Verslype, Chris; Scheithauer, Werner; Shang, Aijing; Cosaert, Jan; Moore, Malcolm J
Informations sur la publication:	Journal of clinical oncology, 27, 13, page (2231-2237)
Statut de publication:	Publié, 2009-05
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Antibodies, Monoclonal -- administration & dosage -- adverse effects
	Antibodies, Monoclonal, Humanized
	Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
	Deoxycytidine -- administration & dosage -- adverse effects -- analogs & derivatives
	Humans
	Neoplasm Metastasis
	Pancreatic Neoplasms -- drug therapy -- mortality -- pathology
	Quinazolines -- administration & dosage -- adverse effects
Note générale:	Clinical Trial, Phase III
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:doi/10.1200/JCO.2008.20.0238
	info:pii/JCO.2008.20.0238
	info:pmid/19307500